Stockscreener 앱 받기
2.34
1.74%
0.04
시간 외 거래:
2.34
전일 마감가:
$2.30
열려 있는:
$2.33
하루 거래량:
158.77K
Relative Volume:
0.42
시가총액:
$19.29M
수익:
$2.00M
순이익/손실:
$-11.43M
주가수익비율:
-1.1957
EPS:
-1.957
순현금흐름:
$-10.05M
1주 성능:
+18.18%
1개월 성능:
+3.54%
6개월 성능:
-36.24%
1년 성능:
-25.36%
1일 변동 폭
$2.26
$2.56
1주일 범위
$1.94
$2.56
52주 변동 폭
$1.81
$12.37
Lipocine Inc Stock (LPCN) Company Profile
명칭
Lipocine Inc
전화
801 994 7383
주소
675 ARAPEEN DRIVE, SUITE 202, SALT LAKE CITY, UT
Compare LPCN vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
LPCN
Lipocine Inc
|
2.34 | 18.88M | 2.00M | -11.43M | -10.05M | -1.957 |
VRTX
Vertex Pharmaceuticals Inc
|
458.99 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
607.93 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
892.26 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
282.72 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
157.77 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Lipocine Inc Stock (LPCN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-06 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2021-06-24 | 개시 | Cantor Fitzgerald | Overweight |
| 2020-12-10 | 업그레이드 | Ladenburg Thalmann | Neutral → Buy |
| 2018-01-12 | 재확인 | H.C. Wainwright | Buy |
| 2018-01-11 | 다운그레이드 | Canaccord Genuity | Buy → Hold |
| 2017-12-08 | 재개 | H.C. Wainwright | Buy |
| 2016-10-07 | 개시 | H.C. Wainwright | Buy |
| 2015-07-22 | 개시 | ROTH Capital | Buy |
| 2015-06-23 | 개시 | Canaccord Genuity | Buy |
모두보기
Lipocine Inc 주식(LPCN)의 최신 뉴스
LPCN Q1 2026 Earnings: EPS Misses Estimates as No Revenue Reported; Stock Edges Higher - newsline.com
Lipocine (LPCN) holds virtual KOL event on postpartum depression and LPCN 1154 - Stock Titan
LPCN: LPCN 1154 demonstrated rapid, sustained PPD relief with a short, well-tolerated oral regimen - TradingView
LPCN Q1 2026 Earnings: Wider-Than-Anticipated Loss Reflects Continued R&D SpendingGuidance Update - newsline.com
Lipocine Inc. (LPCN) Extends Decline: Key Support Levels in Focus After 7% DropStock Analysis - newsline.com
Higuchi John W. buys Lipocine (LPCN) shares worth $252,149 - Investing.com
Lipocine (NASDAQ: LPCN) holders back directors and expand stock incentive plan - Stock Titan
Lipocine (LPCN) director Higuchi awarded right to buy 1,764 shares at $2.19 - Stock Titan
Lipocine (LPCN) director awarded 1,764 stock options at $2.19 exercise price - Stock Titan
Director Richard Dana Ono awarded 1,764 Lipocine (LPCN) stock options at $2.19 - Stock Titan
Lipocine Plans KOL Webinar on Oral PPD Candidate - TipRanks
Lipocine to Host Virtual KOL Event on LPCN 1154 Phase 3 Data for Postpartum Depression - TradingView
Lipocine Inc. to Host Virtual KOL Event Highlighting Unmet Needs in Postpartum Depression and the Clinical Profile of LPCN 1154 - Morningstar
Lipocine (LPCN) Holds Near $2.25 Support Zone as Market Waits for CatalystsIV Crush Alert - newsline.com
LPCN Q1 2026 Earnings: Wider-Than-Expected Loss as Company Continues to Advance PipelineFinancial Health Score - The Legal Advocate
Lipocine Inc. (LPCN) Slips Slightly While Holding Above Established SupportMerger Arbitrage - newsline.com
Lipocine Inc. (LPCN) Edges Higher Amid Modest Uptick: Technical Resistance in SightSector Neutral Pair - newsline.com
Lipocine presents Phase 3 LPCN 1154 data for postpartum depression at ASCP - TradingView
[8-K] Lipocine Inc. Reports Material Event - Stock Titan
Lipocine Inc. (LPCN) Edges Higher as Biotech Stock Holds Above Key SupportDividend ETF - The Legal Advocate
Lipocine Inc. (LPCN) Shows Modest Uptick, Trading Near Key Resistance LevelTRIN Signal - The Legal Advocate
Lipocine Inc. (LPCN) Shows Resilience: Breaking Down the $2.26 RallyVolume Rate Change - thelegaladvocate.com
LPCN SEC FilingsLipocine Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Lipocine (LPCN) reports Q1 loss, beats revenue estimates - MSN
LPCN: Excluding an outlier site, rapid and durable efficacy with strong safety was demonstrated in PPD - TradingView
LPCN: Rapid-acting oral PPD therapy shows promise in subgroups, with funding secured for next trial - TradingView
Lipocine Announces LPCN 1154 Phase 3 Data Accepted for Oral Pres - GuruFocus
Lipocine Announces Phase 3 Data for LPCN 1154 (Oral Brexanolone) in Postpartum Depression Selected for Oral Presentation at 2026 ASCP Annual Meeting 1 - Minichart
Lipocine’s postpartum depression drug data to be presented at ASCP By Investing.com - Investing.com South Africa
Lipocine’s postpartum depression drug data to be presented at ASCP - Investing.com UK
Lipocine Showcases Phase 3 Data for Postpartum Depression - TipRanks
Lipocine Phase 3 LPCN 1154 Data Accepted for Oral Presentation at 2026 ASCP Meeting - TradingView
Lipocine (NASDAQ: LPCN) to present LPCN 1154 Phase 3 postpartum depression data - Stock Titan
Lipocine Announces LPCN 1154 Phase 3 Data Accepted for Oral Presentation at 2026 ASCP Annual Meeting - The Herald Journal
Lipocine to Present at A.G.P.'s Annual Virtual Healthcare Company Showcase - Sahm
Lipocine to Present Innovative Oral Therapeutics Pipeline at A.G.P.’s Annual Virtual Healthcare Showcase 2026 - Minichart
Lipocine Showcases Pipeline at Virtual Healthcare Conference - TipRanks
Lipocine to Present at A.G.P. Virtual Healthcare Showcase May 20 - TradingView
Lipocine (NASDAQ: LPCN) plans fireside chat at A.G.P. Annual Healthcare Company Showcase - Stock Titan
Ikarian Capital (LPCN) reports 508,556 shares, 6.3% ownership - Stock Titan
Squadron Master Fund LP (LPCN) reports 450,000 shares, 6.2% stake - Stock Titan
Lipocine (LPCN) Stock Analysis: Falls -0.91%, Watching $2.18 2026-05-14Virgin POC - newsline.com
LPCN (Lipocine) Q1 loss exceeds estimates by 9.2 percent; shares unmoved as investors await updates.Stock Idea Sharing Hub - newser.com
The numbers behind Lipocine (LPCN) stock nobody talks about (Modest Decline) 2026-05-11Popular Trader Picks - Newser
A. G. P. Maintains Lipocine(LPCN.US) With Buy Rating, Maintains Target Price $6 - Moomoo
Lipocine Inc. Announces First Quarter Financial Results Ending March 31, 2026 - geneonline.com
MSN Money - MSN
Lipocine Inc (LPCN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Lipocine Inc 주식 (LPCN) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Higuchi John W. | Director |
Apr 06 '26 |
Buy |
2.05 |
123,000 |
252,150 |
163,797 |
| Patel Mahesh V. | Chief Executive Officer |
Apr 06 '26 |
Buy |
2.03 |
25,000 |
50,750 |
160,679 |
| Patel Mahesh V. | Chief Executive Officer |
Apr 02 '26 |
Buy |
2.02 |
25,000 |
50,500 |
135,679 |
2.60%
0.94%
자본화:
|
볼륨(24시간):